argenex SE (NASDAQ:ARGX) Receives Average Rating of “Moderate Buy” from Brokerages

argenex SE (NASDAQ:ARGX) has been assigned a consensus recommendation of “Moderate Buy” from the twenty-four ratings firms that are covering the stock, MarketBeat Ratings reports. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokerages that have issued a report on the stock in the last year is $986.7778.

A number of brokerages have weighed in on ARGX. Zacks Research downgraded argenex from a “hold” rating to a “strong sell” rating in a report on Thursday, January 22nd. Wedbush reaffirmed an “outperform” rating and issued a $1,000.00 price objective on shares of argenex in a research note on Wednesday, January 14th. Piper Sandler boosted their target price on argenex from $820.00 to $930.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 4th. Citigroup reduced their price target on shares of argenex from $1,124.00 to $1,091.00 and set a “buy” rating on the stock in a research note on Thursday, January 8th. Finally, Stifel Nicolaus lifted their price target on shares of argenex from $1,028.00 to $1,248.00 and gave the company a “buy” rating in a report on Thursday, December 11th.

argenex Trading Up 2.3%

Shares of NASDAQ:ARGX opened at $833.16 on Tuesday. The firm has a 50 day moving average of $857.54 and a 200-day moving average of $776.33. argenex has a 12 month low of $510.05 and a 12 month high of $934.62. The stock has a market capitalization of $51.56 billion, a PE ratio of 35.77, a PEG ratio of 0.54 and a beta of 0.38.

argenex (NASDAQ:ARGX) last posted its quarterly earnings results on Thursday, October 30th. The company reported $4.40 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.37 by $0.03. argenex had a net margin of 41.58% and a return on equity of 29.78%. The business had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.07 billion. On average, research analysts predict that argenex will post 3.13 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in ARGX. Merit Financial Group LLC grew its holdings in argenex by 4.7% during the 4th quarter. Merit Financial Group LLC now owns 377 shares of the company’s stock worth $317,000 after acquiring an additional 17 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its stake in shares of argenex by 22.9% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 10,846 shares of the company’s stock valued at $9,121,000 after buying an additional 2,018 shares during the period. CWM LLC increased its stake in shares of argenex by 14.1% in the fourth quarter. CWM LLC now owns 412 shares of the company’s stock valued at $347,000 after buying an additional 51 shares during the period. Farther Finance Advisors LLC raised its position in shares of argenex by 99.4% during the fourth quarter. Farther Finance Advisors LLC now owns 355 shares of the company’s stock worth $299,000 after acquiring an additional 177 shares during the last quarter. Finally, Choreo LLC lifted its stake in shares of argenex by 20.5% in the fourth quarter. Choreo LLC now owns 724 shares of the company’s stock worth $607,000 after acquiring an additional 123 shares during the period. Institutional investors own 60.32% of the company’s stock.

argenex Company Profile

argenx (NASDAQ: ARGX) is a biotechnology company focused on the discovery, development and commercialization of antibody-based therapeutics for severe autoimmune and neuromuscular diseases. The company uses its proprietary SIMPLE Antibody platform to generate differentiated antibodies and engineered Fc regions, and it pursues mechanisms that modulate the neonatal Fc receptor (FcRn) to reduce pathogenic IgG levels. Argenx’s research and development activities span target identification, preclinical development and late-stage clinical programs aimed at addressing unmet needs in immunology.

The company’s lead product, efgartigimod (marketed as Vyvgart), is an FcRn antagonist developed to reduce circulating IgG antibodies and treat IgG-mediated disorders.